Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 20:11:671969.
doi: 10.3389/fonc.2021.671969. eCollection 2021.

Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study

Nicolas Epaillard  1 , Pauline Parent  2 , Yohann Loriot  2 , Pernelle Lavaud  2 , E-B Vera-Cea  3 , Nieves Martinez-Chanza  4 , Alejo Rodriguez-Vida  3 , Clement Dumont  5 , Rebeca Lozano  6   7 , Casilda Llácer  7 , Raffaele Ratta  8 , Stephane Oudard  1 , Constance Thibault  1 , Edouard Auclin  1
Affiliations

Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study

Nicolas Epaillard et al. Front Oncol. .

Abstract

Introduction: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.

Materials: Multicenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS).

Results: Between 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type.

Conclusion: Chemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature.

Keywords: drug therapy; immunotherapy; mortality; urinary bladder neoplasms; variant histology.

PubMed Disclaimer

Conflict of interest statement

YL reports Grant, personal fees and nonfinancial support from Janssen and MSD; personal fees and nonfinancial support from Astellas, Roche, AstraZeneca, BMS and Seattle Genetics; grant and personal fees from Sanofi; personal fees from Clovis, Incyte and Pfizer. PL reports conflict of interest with IPSEN Mundi Pharma JANSSEN Astellas Pfizer Astra Zeneca. AR-V reports serving in an advisory role for MSD, Pfizer, BMS, Astellas, Janssen, Bayer, Clovis and Roche; receiving honoraria or travel expenses from Pfizer, MSD, Astellas, BMS, Janssen, Astra Zeneca, Roche, Bayer, and Sanofi Aventis; and receiving research funding from Takeda, Pfizer, and MSD. NM-C reports support for research travel from Pfizer, Janssen and Ipsen, and consulting fees for BMS, Pfizer, Sanofi and Bayer. CD reports consulting or Advisory Role: Pfizer. Travel, Accommodations, Expenses: Ipsen, Pfizer, MSD. CL reports Speakers’ bureau: Roche. Travel, Accommodations, Expenses: Astellas Pharma, Angelini Pharma. RR reports Consulting/Advisory board: Pfizer, MSD; Travel, Accommodations, Expenses: Pfizer. SO declares honoraria from Sanofi, Astellas, Janssen, Bayer, Pfizer, Novartis, Ipsen, MSD, BMS, and Astra Zeneca. CT declares Board: BMS, Pfizer, Pfizer, Ipsen, MSD, Astellas, Janssen, AstraZeneca, Merck, Sanofi. Travel: Pfizer, Sanofi, AstraZeneca. Funding: AstraZeneca, Sanofi. EA reports Travel expenses: Mundipharma. Lectures and educational activities: Sanofi Genzymes. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart. L1, First-line therapy; L2, Second-line therapy; L3, Third-line therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Estimating the global cancer incidence and mortality in 2018 . GLOBOCAN Sources and Methods - Ferlay - 2019 - International Journal of Cancer - Wiley Online Library. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31937. - PubMed
    1. Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, et al. . Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients With Advanced non-Transitional Cell Carcinoma of the Urothelial Tract. Urology (2007) 69(2):255−9. 10.1016/j.urology.2006.10.029 - DOI - PubMed
    1. Martin JW, Carballido EM, Ahmed A, Farhan B, Dutta R, Smith C, et al. . Squamous Cell Carcinoma of the Urinary Bladder: Systematic Review of Clinical Characteristics and Therapeutic Approaches. Arab J Urol (2016) 14(3):183−91. 10.1016/j.aju.2016.07.001 - DOI - PMC - PubMed
    1. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu C-L, Wu S, et al. . Clinical Outcomes of Patients With Histologic Variants of Urothelial Cancer Treated With Trimodality Bladder-Sparing Therapy. Eur Urol (2017) 72(1):54–60. 10.1016/j.eururo.2016.12.002 - DOI - PubMed
    1. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol (2016) 70(1):106–19. 10.1016/j.eururo.2016.02.028 - DOI - PubMed